Imatinib

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instanceOf gptkb:receptor_tyrosine_kinase
gptkb:drug
gptkbp:administeredBy gptkb:tablet
gptkbp:approvalYear 2001
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode L01EA01
gptkbp:brand gptkb:Gleevec
gptkb:Glivec
gptkbp:CASNumber 152459-95-5
gptkbp:category protease inhibitor
antineoplastic agent
orphan drug
gptkbp:contraindication pregnancy
hypersensitivity to imatinib
gptkbp:cost high (in US, before generics)
gptkbp:developedBy gptkb:Novartis
gptkbp:discoveredBy gptkb:Brian_Druker
gptkb:Nicholas_Lydon
gptkbp:eliminationHalfLife 18 hours
gptkbp:excretion urine
feces
gptkbp:firstSynthesized 1992
gptkbp:genericAvailable yes
gptkbp:hasMolecularFormula C29H31N7O
https://www.w3.org/2000/01/rdf-schema#label Imatinib
gptkbp:interactsWith CYP3A4 inhibitors
CYP3A4 inducers
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits BCR-ABL tyrosine kinase
inhibits c-KIT
inhibits PDGF receptor
gptkbp:metabolism liver (CYP3A4)
gptkbp:molecularWeight 493.6 g/mol
gptkbp:patentExpired yes
gptkbp:pregnancyCategory D (US)
gptkbp:PubChem_CID gptkb:CHEMBL941
5291
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
diarrhea
edema
fatigue
rash
muscle cramps
gptkbp:UNII 8CIP0O835V
gptkbp:usedFor gptkb:gastrointestinal_stromal_tumor
gptkb:chronic_myeloid_leukemia
gptkb:systemic_mastocytosis
gptkb:dermatofibrosarcoma_protuberans
leukemia
hypereosinophilic syndrome
gptkbp:WHOModelListOfEssentialMedicines included
gptkbp:bfsParent gptkb:CHEMBL958
gptkb:112809-51-5
gptkbp:bfsLayer 6